HomeCompareCMOPF vs GIS

CMOPF vs GIS: Dividend Comparison 2026

CMOPF yields 2.29% · GIS yields 6.53%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GIS wins by $55.8K in total portfolio value
10 years
CMOPF
CMOPF
● Live price
2.29%
Share price
$105.00
Annual div
$2.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.1K
Annual income
$264.93
Full CMOPF calculator →
GIS
GIS
● Live price
6.53%
Share price
$37.22
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.8K
Annual income
$16,211.26
Full GIS calculator →

Portfolio growth — CMOPF vs GIS

📍 GIS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMOPFGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMOPF + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMOPF pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMOPF
Annual income on $10K today (after 15% tax)
$194.28/yr
After 10yr DRIP, annual income (after tax)
$225.19/yr
GIS
Annual income on $10K today (after 15% tax)
$554.94/yr
After 10yr DRIP, annual income (after tax)
$13,779.57/yr
At 15% tax rate, GIS beats the other by $13,554.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMOPF + GIS for your $10,000?

CMOPF: 50%GIS: 50%
100% GIS50/50100% CMOPF
Portfolio after 10yr
$51.0K
Annual income
$8,238.10/yr
Blended yield
16.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

CMOPF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
9.2
Piotroski
8/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.4% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMOPF buys
0
GIS buys
0
No recent congressional trades found for CMOPF or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMOPFGIS
Forward yield2.29%6.53%
Annual dividend / share$2.40$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$23.1K$78.8K
Annual income after 10y$264.93$16,211.26
Total dividends collected$2.5K$50.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: CMOPF vs GIS ($10,000, DRIP)

YearCMOPF PortfolioCMOPF Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$10,929$228.56$11,502$801.73$573.00GIS
2$11,927$233.45$13,365$1,058.29$1.4KGIS
3$13,000$238.11$15,712$1,411.34$2.7KGIS
4$14,153$242.55$18,716$1,904.17$4.6KGIS
5$15,390$246.78$22,629$2,603.16$7.2KGIS
6$16,718$250.80$27,826$3,612.21$11.1KGIS
7$18,143$254.62$34,871$5,097.54$16.7KGIS
8$19,671$258.24$44,643$7,331.52$25.0KGIS
9$21,310$261.68$58,541$10,772.15$37.2KGIS
10$23,067$264.93$78,850$16,211.26$55.8KGIS

CMOPF vs GIS: Complete Analysis 2026

CMOPFStock

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Full CMOPF Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this CMOPF vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMOPF vs SCHDCMOPF vs JEPICMOPF vs OCMOPF vs KOCMOPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.